Clinical Trials Browser

Phase 3 × Withdrawn × Erlotinib Hydrochloride × Clear all

NCT03529084 2019-11-22

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02795884 2016-12-30

Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

Phase 3 Withdrawn

Lung Neoplasms